EDITION OF SAT 26 SEP 2026
202 · BUSINESS

Kyverna Reports One-Year Autoimmune CAR-T Data, Targets BLA Completion

publishers 6articles 6first reported 24 Sep, 10:02 UTCdeveloping since 25 Sep · 2 editions

Kyverna said one-year data for its CAR-T therapy miv-cel showed durable, drug-free remission and a favorable safety profile in patients with stiff person syndrome and generalized myasthenia gravis. The company said the longer-term results support its planned FDA submission for the rare autoimmune therapy.

Kyverna is aiming to complete its biologics license application for miv-cel in stiff person syndrome this year. If approved, the treatment could become the first CAR-T therapy cleared by the FDA for an autoimmune condition.

HOW THIS STORY WAS MADE

Written from 6 articles, headlines and summaries only; 6 independent newsrooms once syndicated copies count as one; this version written 6 h after the record first saw the story; the editor kept it as written.

Publishers
6
Source articles
6
Given to the writer
6, headlines and summaries only
Independent newsrooms
6
This version written
6 h after the record first saw the story
Second model (editor)
kept as written
Publication gate
passed
Human review
none

WHAT THE EDITOR DID

The second model checked the writer's draft against the same sources and published it as written.

Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →

NAMED IN THE COVERAGE

OUTLETS CARRYING THE STORY, RUN BY RUN

0 3 6 26 Sep 25 Sep 06:25 UTC · Kyverna reports one-year autoimmune CAR-T data for miv-cel 25 Sep 12:26 UTC · Kyverna Reports One-Year Autoimmune CAR-T Data, Targets BLA Completion

WHAT HELD, WHAT CAME LATER

From the first reports to the latest

  • Nothing ran from the first third of the coverage to the last.

Entered the story later

  • Nothing new took hold after the first third.

HOW THIS STORY DEVELOPED: EVERY HEADLINE, EVERY OUTLET →